**Supplement 3**. Common scenarios in which proton pump inhibitor gastroprotection is recommended. It should be noted that additional guidance regarding testing for H. pylori and selection of appropriate NSAID formulations is not included in this table and can be found in the relevant guidelines

|  |  |  |
| --- | --- | --- |
|  | Relevant guideline | Evidence Grade |
| Dual anti-platelet therapy | Bhatt, 2008 and Abraham, 2010Valgimigli, 2017 | Not gradedGRADE IB |
| Anti-platelet drug plus NSAID | Bhatt, 2008Lanza, 2009 | Not gradedGRADE 2C |
| ASA plus anticoagulation | Bhatt, 2008 | Not graded |
| History of ulcer bleeding with ongoing use of any NSAID, antiplatelet therapy or anticoagulation | Bhatt 2008Barkun, 2019Lanza, 2009 | Not gradedGRADE 2CGRADE 1B |
| Patients using NSAIDs with any of the following additional risk factors: age>65 years, high dose NSAID therapy, a previous uncomplicated ulcer, concurrent use of aspirin | Lanza 2009 | GRADE 2C |
| Patients using aspirin with any 2 of the following: age >60, corticosteroid use, dyspepsia or GERD symptoms | Bhatt, 2008 | Not graded |

GERD = gastroesophageal reflux disease; NSAIDs = nonsteroidal anti-inflammatory drugs; PPI = proton pump inhibitor